Next-Gen TYK2 Inhibition: Redefining Oral, Systemic Treatment for Psoriasis

In this session, Jason Hawkes, MD, explores the next wave of TYK2 inhibitors and how emerging molecules differ from first-generation agents. Dr Hawkes discusses the immunologic rationale for targeting the TYK2 pathway in plaque psoriasis and why these therapies represent an exciting step forward in oral treatment options.

He also reviews how to recognize the “systemic-ready” patient, including those who remain undertreated due to limited body surface involvement, and how understanding the immunology behind TYK2 inhibition can help clinicians translate these advances into more effective, individualized care.